aTyr Pharma to Present at Life Sciences Investor Forum on September 17th
September 02, 2020 07:00 ET
|
Life Sciences Investor Forum
SAN DIEGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (the “Company”) (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on...
Assembly Biosciences and Arbutus Biopharma Announce Clinical Collaboration Agreement to Evaluate the Combination of Core Inhibitor ABI-H0731 with RNAi Therapeutic AB-729 in Patients with Chronic Hepatitis B Virus Infection
August 27, 2020 08:00 ET
|
Arbutus Biopharma Corporation; Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif. and WARMINSTER, Pa., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB) and Arbutus Biopharma Corporation (Nasdaq: ABUS), today announced that...
BioCardia to Present at the LD Micro 500 Virtual Conference on September 1, 2020
August 26, 2020 07:00 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., Aug. 26, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies today...
BioCardia Reports Second Quarter 2020 Financial Results and Business Highlights
August 13, 2020 07:00 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today...
BioCardia To Conduct Mid-Year Conference Call and Corporate Update August 13, 2020
August 07, 2020 08:00 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., Aug. 07, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today...
Cellectis Provides Business Update and Reports Financial Results for Second Quarter and First Six Months 2020
August 05, 2020 16:30 ET
|
Cellectis Inc.
Enrollment ongoing in Phase 1 dose-escalation trial BALLI-01 in r/r B-ALL patientsEnrollment ongoing in Phase 1 dose-escalation trial AMELI-01 in r/r AML patients MELANI-01 trial in r/r MM patients on...
Cellectis to Hold Second Quarter 2020 Earnings Call on Thursday, August 6, 2020 at 7:30AM EDT
July 29, 2020 16:30 ET
|
Cellectis Inc.
NEW YORK, July 29, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited...
Cellectis Appoints Biopharma Veteran Steve Doares, Ph.D., as Senior Vice President of US Manufacturing
July 21, 2020 16:30 ET
|
Cellectis Inc.
NEW YORK, July 21, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited...
BioSpace 2020 Salary Report: While Life Sciences Professionals Report an Overall Increase in Base Salary, Gender Gap Continues to Widen
July 16, 2020 09:00 ET
|
BioSpace, Inc.
DES MOINES, Iowa, July 16, 2020 (GLOBE NEWSWIRE) -- BioSpace Inc., the leader in life sciences news and careers, announced today that they have released the BioSpace 2020 Salary Report. In the...
CURE Pharmaceutical CBD Oral Thin Film Pharmacokinetic Study Shows Improved Bioavailability Compared to CBD Soft Gel
July 15, 2020 08:00 ET
|
CURE Pharmaceutical Holding Corp.
OXNARD, Calif., July 15, 2020 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced that its 25mg cannabidiol (CBD) oral thin film...